ClinicalTrials.gg
RecruitingNCT06976190Magic-C002Updated Aug 31, 2026

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

A Phase 3 interventional study of MRG003 + Pucotenlimab and Gemcitabine, Docetaxel, or Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma, sponsored by Lepu Biopharma Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Primary conditionNasopharyngeal CarcinomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nasopharyngeal Carcinoma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Nasopharyngeal Carcinoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Lepu Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing becotatug vedotin in Nasopharyngeal Carcinoma — 8 open to participants now, 10 under way, 2 of them phase 3. becotatug vedotin · Nasopharyngeal Carcinoma.

Planned enrollment
Largest of 10
446 · median 43
Started
2025
the only one that year
Phase 3
2 of 10
2 open now
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Lepu Biopharma Co., Ltd.

Among the 10 studies testing becotatug vedotin in Nasopharyngeal Carcinoma, this one has the largest planned enrollment, is the only one that started in 2025, is one of 2 in phase 3, and was the 2nd registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

8 of the 10 studies testing becotatug vedotin in Nasopharyngeal Carcinoma are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About becotatug vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing becotatug vedotin in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.

03

Conditions studied

  • Recurrent or Metastatic Nasopharyngeal Carcinoma

Browse trials for

Keywords

  • MRG003
  • Pucotenlimab
  • Nasopharyngeal Carcinoma
04

In context

Nasopharyngeal Carcinoma Reclassified

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

This study's planned enrollment of 446 is above the median of 100 across 557 interventional studies indexed under Nasopharyngeal Carcinoma.

Browse Nasopharyngeal Carcinoma studies →

Lead sponsor

Lepu Biopharma Co., Ltd. is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Compared within Nasopharyngeal Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to sign the form and follow the requirements specified in the protocol.
  • ≥ 12 weeks.
  • Patients with and cytologically confirmed recurrent or nasopharyngeal carcinoma (NPC) who have failed at least one line of prior systemic therapy.
  • Patients must have at least one according to the (RECIST v1.1).
  • The score of for performance status is 0 or 1.
  • No severe cardiac dysfunction, (LVEF) ≥50%.
  • Organ functions and coagulation function must meet the basic requirements.
  • Patients with must use effective during the treatment and for 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  • History of to any component of the product.
  • Received systemic chemotherapy, targeted therapy, biological therapy or immunotherapy for anti-tumor purpose, or major surgery within 3 weeks prior to the first dose of study treatment.
  • Received anti-infection therapy within 2 weeks prior to the randomization
  • Prior treatment with MMAE/MMAF ADC drugs
  • Central nervous system .
  • Poorly controlled systemic diseases
  • Patients with poorly controlled heart diseases
  • Poorly controlled pleural and peritoneal effusion or pericardial effusion
  • ≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment
  • Patients with prior ≥Grade 3 immuno-related adverse events (irAEs)
  • Any arteriovenous bleeding, pulmonary embolism, or deep venous thrombosis occurred within 3 months
  • Received allogeneic tissue/solid organ transplantation.
  • Inoculate within 30 days before the first dose.
  • Patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate measures during the treatment and for 180 days after the last dose of study treatment.
  • History of other primary malignant tumor diseases.
  • Other situations that are not suitable to participate a clinical trial per investigator's judgement
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
446 participants (estimated)

Study arms

  • Experimental
    MRG003 + Pucotenlimab

    Drug: MRG003 + Pucotenlimab

  • Active comparator
    Chemotherapy Arm

    Mono-chemotherapy as selected by investigator

    Drug: Gemcitabine, Docetaxel, or Capecitabine

Interventions

  • DrugMRG003 + Pucotenlimab

    Drug pages: Becotatug vedotin · Pucotenlimab

    MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.

  • DrugGemcitabine, Docetaxel, or Capecitabine

    Gemcitabine will be administrated via intravenous infusion at 1000 mg/m2 once on Day 1 and 8 of every 3 weeks (21-day cycle). Docetaxel will be administrated via intravenous infusion at 75 mg/m2 once on Day 1 of every 3 weeks (21-day cycle). Capecitabine will be administrated orally at 1000 mg/m2 twice a day for Day 1 to 14 of every 3 weeks (21-day cycle).

07

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as assessed by BIRC

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion (up to 33 months)

  2. Overall Survival (OS)

    OS is defined as the duration from the start of treatment to death of any cause.

    Time frame: Baseline to study completion (up to 48 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 48 months)

  2. Disease Control Rate (DCR)

    DCR is defined as the proportion of subjects achieving CR, PR, and stable disease (SD) after treatment.

    Time frame: Baseline to study completion (up to 48 months)

  3. Progression Free Survival (PFS) as assessed by investigator

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion (up to 33 months)

  4. Immunogenicity (ADA)

    The proportion of patients with positive ADA results.

    Time frame: Baseline to 14 days after the last dose.

  5. Adverse Events (AEs)

    Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.

    Time frame: Baseline to 30 days after the last dose of study treatment

  6. Serious Adverse Events (SAEs)

    Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability/incapacity/substantial disruption of the ability to lead a normal life, congenital anomaly/birth defect or major medical events or reactions.

    Time frame: Baseline to 30 days after the last dose of study treatment

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.

Of 84 phase 3 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 82. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartActual
May 6, 2025
Primary completionEst.
May 2029
CompletionEst.
Dec 2030
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06976190
Lead sponsor
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
May 16, 2025
Start date
May 6, 2025
Primary completion
May 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 31, 2026

Study contacts

Program Director
Contact
clinicaltrials@miracogen.com.cn
86-21-61637960
Ruihua Xu, M.D.
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Becotatug vedotin · Pucotenlimab

Start the discussion